Glukokortikoidinduceret diabetes og risikofaktorer under højdosisbehandling

TY - JOUR

T1 - Glukokortikoidinduceret diabetes og risikofaktorer under højdosisbehandling

AU - Patel, Dustin Andersen

AU - Kristensen, Peter Lommer

AU - Pedersen-Bjergaard, Ulrik

AU - Schultz, Helga Holm

PY - 2018

Y1 - 2018

N2 - This review describes the cumulative incidence (CI) and risk factors of glucocorticoid (GC)-induced diabetes in patients commencing high-dose GC therapy: ≥ 30 mg prednisolone/day. Finally, methods of screening are discussed. In 13 studies, the CI of GC-induced diabetes ranges 12-65%, but with the current diagnostic criteria the CI is assessed to be 30-50%. Risk factors may include high age and high levels of BMI and glycated haemoglobin, respectively, before GC therapy. It is important to acknowledge, that hyperglycaemia in GC therapy is more prevalent postprandially, and screening should be planned accordingly.

AB - This review describes the cumulative incidence (CI) and risk factors of glucocorticoid (GC)-induced diabetes in patients commencing high-dose GC therapy: ≥ 30 mg prednisolone/day. Finally, methods of screening are discussed. In 13 studies, the CI of GC-induced diabetes ranges 12-65%, but with the current diagnostic criteria the CI is assessed to be 30-50%. Risk factors may include high age and high levels of BMI and glycated haemoglobin, respectively, before GC therapy. It is important to acknowledge, that hyperglycaemia in GC therapy is more prevalent postprandially, and screening should be planned accordingly.

M3 - Tidsskriftartikel

C2 - 29720341

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V06170454

ER -